PL2932968T3 - Związek do leczenia stanów pośredniczonych alfa-adrenergicznie - Google Patents

Związek do leczenia stanów pośredniczonych alfa-adrenergicznie

Info

Publication number
PL2932968T3
PL2932968T3 PL15165926T PL15165926T PL2932968T3 PL 2932968 T3 PL2932968 T3 PL 2932968T3 PL 15165926 T PL15165926 T PL 15165926T PL 15165926 T PL15165926 T PL 15165926T PL 2932968 T3 PL2932968 T3 PL 2932968T3
Authority
PL
Poland
Prior art keywords
compound
mediated conditions
alpha adrenergic
treating alpha
adrenergic mediated
Prior art date
Application number
PL15165926T
Other languages
English (en)
Inventor
Wenkui K. Fang
Phong X. Nguyen
Ken Chow
Todd M. Heidelbaugh
Dario G. Gomez
Michael E. Garst
Santosh C. Sinha
Daniel W. Gil
John E. Donello
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL2932968T3 publication Critical patent/PL2932968T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
PL15165926T 2008-06-09 2009-06-05 Związek do leczenia stanów pośredniczonych alfa-adrenergicznie PL2932968T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5983708P 2008-06-09 2008-06-09
EP15165926.5A EP2932968B1 (en) 2008-06-09 2009-06-05 Compound for treating alpha adrenergic mediated conditions
EP09763343.2A EP2303264B1 (en) 2008-06-09 2009-06-05 Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives

Publications (1)

Publication Number Publication Date
PL2932968T3 true PL2932968T3 (pl) 2018-06-29

Family

ID=40823137

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09763343T PL2303264T3 (pl) 2008-06-09 2009-06-05 Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny
PL15165926T PL2932968T3 (pl) 2008-06-09 2009-06-05 Związek do leczenia stanów pośredniczonych alfa-adrenergicznie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09763343T PL2303264T3 (pl) 2008-06-09 2009-06-05 Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny

Country Status (14)

Country Link
US (2) US8071636B2 (pl)
EP (3) EP2377534A1 (pl)
JP (1) JP5571072B2 (pl)
CN (1) CN102099032B (pl)
AU (1) AU2009257692A1 (pl)
CA (3) CA2959793A1 (pl)
DK (2) DK2932968T3 (pl)
ES (2) ES2672777T3 (pl)
HU (1) HUE039357T2 (pl)
PL (2) PL2303264T3 (pl)
PT (2) PT2303264T (pl)
SI (1) SI2303264T1 (pl)
TR (1) TR201802766T4 (pl)
WO (1) WO2009152052A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083508A1 (en) * 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
HUE038366T2 (hu) 2010-08-16 2018-10-29 Allergan Inc Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához
LT3662910T (lt) * 2014-03-31 2024-12-27 The Scripps Research Institute Trail geno indukcijai skirtas farmakoforas
JP7837141B2 (ja) 2017-10-27 2026-03-30 シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド αタンパク質キナーゼ１を活性化することによって免疫応答をモジュレートするための組成物および方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6708160A (pl) * 1966-06-30 1968-01-02
DE2259160A1 (de) * 1972-12-02 1974-06-06 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel
US4256755A (en) 1980-04-28 1981-03-17 E. I. Du Pont De Nemours & Company Method of using N-substituted dihydro-2-oxazolamines as analgesics
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
EP1333028A1 (en) * 2002-01-31 2003-08-06 Boehringer Ingelheim Pharma GmbH & Co.KG 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
BRPI0610817A2 (pt) 2005-05-19 2010-07-27 Bayer Cropscience Ag derivados heterocìclicos e heteroarila com substituição benzilamino inseticidas
WO2008123821A1 (en) * 2007-03-01 2008-10-16 Albireo Ab 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders
WO2009003868A2 (en) * 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists

Also Published As

Publication number Publication date
DK2303264T3 (en) 2018-05-22
TR201802766T4 (tr) 2018-03-21
CN102099032B (zh) 2014-07-09
CA2959793A1 (en) 2009-12-17
WO2009152052A8 (en) 2010-11-11
ES2672777T3 (es) 2018-06-18
US8071636B2 (en) 2011-12-06
EP2303264B1 (en) 2018-04-04
SI2303264T1 (en) 2018-08-31
PT2932968T (pt) 2018-03-13
EP2932968B1 (en) 2018-01-17
HUE039357T2 (hu) 2018-12-28
JP2011522893A (ja) 2011-08-04
EP2932968A1 (en) 2015-10-21
CA2744929C (en) 2017-07-25
ES2665293T3 (es) 2018-04-25
WO2009152052A1 (en) 2009-12-17
PT2303264T (pt) 2018-05-14
EP2303264A1 (en) 2011-04-06
CA3133261A1 (en) 2009-12-17
DK2932968T3 (en) 2018-03-12
HK1214132A1 (en) 2016-07-22
PL2303264T3 (pl) 2018-08-31
US20120035235A1 (en) 2012-02-09
JP5571072B2 (ja) 2014-08-13
US20090306161A1 (en) 2009-12-10
CA2744929A1 (en) 2009-12-17
AU2009257692A1 (en) 2009-12-17
EP2377534A1 (en) 2011-10-19
CN102099032A (zh) 2011-06-15

Similar Documents

Publication Publication Date Title
IL209895A0 (en) Compounds for treating beta-amyloidoses
IL257418A (en) Methods for treating addiction
GB0806422D0 (en) Process
GB0806419D0 (en) Process
GB0808836D0 (en) Process
IL209894A0 (en) Compounds for treating amyloidoses
IL208069A0 (en) Methods for treating psoriasis
IL213398A0 (en) Compounds for treating cancer
GB0803669D0 (en) Process
GB0801580D0 (en) Process
GB0801209D0 (en) Process
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
IL212212A0 (en) Compound useful for treating cellulite
IL211904A0 (en) Composition for treating disese
GB0800875D0 (en) Process
EP2285385A4 (en) COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
PL2932968T3 (pl) Związek do leczenia stanów pośredniczonych alfa-adrenergicznie
IL213287A0 (en) Treatment for glomerulonephritis
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
GB0807161D0 (en) Process
GB0803960D0 (en) Process
GB0808764D0 (en) Process
GB0808357D0 (en) Process
GB0803663D0 (en) Process
GB0808359D0 (en) Process